Pharmacodynamic modeling of time-dependent transduction systems.
about
Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of erlotinib in a human non-small cell lung cancer xenograft mouse model.Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systemsDifferential pharmacodynamic effects of paclitaxel formulations in an intracranial rat brain tumor model.A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis.Multiscale model for the assessment of autonomic dysfunction in human endotoxemia.Pharmacodynamic differentiation of lorazepam sleepiness and dizziness using an ordered categorical measureTissue-level modeling of xenobiotic metabolism in liver: An emerging tool for enabling clinical translational researchPharmacokinetic and pharmacodynamic analysis comparing diverse effects of detomidine, medetomidine, and dexmedetomidine in the horse: a population analysis.Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response.Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities.Pharmacodynamic analysis of recombinant human erythropoietin effect on reticulocyte production rate and age distribution in healthy subjectsA Systems Pharmacology Model of Erythropoiesis in Mice Induced by Small Molecule Inhibitor of Prolyl Hydroxylase Enzymes.Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons.Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response modelsPKPD modelling to predict altered disposition of 1α,25-dihydroxyvitamin D3 in mice due to dose-dependent regulation of CYP27B1 on synthesis and CYP24A1 on degradation.Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamicsLogic-Based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma Cells.Population pharmacokinetic-pharmacodynamic-disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritis.Pharmacokinetic-pharmacodynamic modelling: history and perspectives.Population PK/PD analysis of metformin using the signal transduction model.Bridging Clinical Outcomes of Canakinumab Treatment in Patients With Rheumatoid Arthritis With a Population Model of IL-1β Kinetics.Applications of quantitative pharmacodynamic effect markers in drug target identification and therapy developmentMechanism-based pharmacodynamic modeling.Scaling pharmacodynamics from in vitro and preclinical animal studies to humans.Moving from basic toward systems pharmacodynamic models.Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer.Pharmacokinetic-pharmacodynamic modeling of the antitumor effect of TM208 and EGFR-TKI resistance in human breast cancer xenograft miceLifespan based indirect response models.Modeling of delays in PKPD: classical approaches and a tutorial for delay differential equations.Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity.Array of translational systems pharmacodynamic models of anti-cancer drugs.Enhancing value of clinical pharmacodynamics in oncology drug development: An alliance between quantitative pharmacology and translational science.Pharmacodynamic modeling of chemotherapeutic effects: application of a transit compartment model to characterize methotrexate effects in vitro.Pharmacokinetic/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine.Quantitative insight in utilizing circulating angiogenic factors as biomarkers for antiangiogenic therapy: systems pharmacology approach.Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.Pharmacokinetic/pharmacodynamic modelling of 2-acetyl-4(5)-tetrahydroxybutyl imidazole-induced peripheral lymphocyte sequestration through increasing lymphoid sphingosine 1-phosphate.Pharmacokinetics and Pharmacodynamics of the Triterpenoid Ursolic Acid in Regulating the Antioxidant, Anti-inflammatory, and Epigenetic Gene Responses in Rat Leukocytes.Bioanalytical considerations in the comparability assessment of biotherapeutics.Systems analysis of digoxin kinetics and inotropic response in the rat heart: effects of calcium and KB-R7943.
P2860
Q33551899-F7641E91-C684-4122-8A73-01903BC3D53EQ33611516-E9FAFD99-7816-4FCA-A5D0-C19BF2DE653AQ33613579-2B0C709E-8468-42A5-A3E4-FC128A31590AQ33729213-55A879C3-CC0B-4D26-9F91-A409EDB649E9Q33924871-A474CEA9-B371-4EE6-A65A-1AE6CF19AA3AQ34055606-CF53CC29-9538-425E-93B4-1C6E08A0FDA0Q34746268-F0E962B5-6EF4-44CD-9E89-E480FE6C7F4FQ34860261-E7A9D67E-738F-4041-A355-5F4BCF625BB3Q34953673-8A786A4C-B56A-460C-8501-1392CD862BD1Q35104052-C5D0E6C4-A693-48C7-B4BF-7CF2C6561F14Q35132886-68B95DBD-58AF-490C-9170-FF21F8D7B653Q35179547-FAEFBDC1-33C2-4C9A-88D1-5FB14FC2BF6EQ35223673-8B094D93-A86D-4995-8488-6BE3706D7A50Q35226129-8276B9C6-2037-419F-8A60-6CF4AECFFAD5Q35865449-A0198E3D-9CDD-4488-BABE-45B84BB9BE11Q35919697-9635975E-205E-42E8-9435-65E11CD41A05Q35962054-CEF021FF-3BAD-4CF1-A308-9952CA840D41Q36125978-693B7AC7-F446-49C5-BBC5-1C893CE489E6Q36365141-97322E7D-20EC-4A31-8F94-F7380DECDB44Q36390254-59107235-DFCB-4DB0-85DD-E3BBDBD52DA9Q36702456-514AF8A2-DA5A-4130-B7D9-05E9CEE9B420Q36861319-F5D9EC24-48DC-4321-B4E1-8DF1CB863CD2Q36933670-2FC4C796-973A-4C99-AF09-E7EE0E33053AQ37055123-3514DC7A-5D71-4C0D-A604-C765220F53E3Q37096317-70ED9A31-31D7-4C23-BF9C-50569112D9E5Q37100575-C36EE25B-CEE4-45ED-9512-8BC9E0C409E4Q37112320-70DFBE78-7AC3-42A6-964F-D1614E4BEB73Q37972792-5EDAB358-20F0-4658-AE51-550727510399Q38241696-56330C77-FBA8-442D-AD7A-A4EFE517CD88Q38962519-64CF7353-312C-421D-AC9B-18494BA5231AQ38988505-35265921-EB3B-4D01-BEC1-ABCE9AF9EA52Q38996431-4A3F99FF-6857-429A-AF09-EC9487121141Q40662868-B3B47CB5-0F37-427A-9234-FE38B90128A9Q42104275-A1EADCA4-7809-4C57-9821-6BA1CA2AA7C5Q42418396-98F38529-027E-41B4-922D-82B0FFF07D50Q42575030-DA297E42-CA7D-450A-8C7B-2D045A2DA479Q43154123-93CC4745-C143-4F4E-B268-1C34D820CA1BQ44236747-BB80DF83-69CC-4A35-B005-147F8F5D97A7Q44701500-57D651E2-0DF3-47ED-BE52-86103A4F4AFAQ44886437-9B458268-82C3-4178-ADF2-50247ACC3F49
P2860
Pharmacodynamic modeling of time-dependent transduction systems.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Pharmacodynamic modeling of time-dependent transduction systems.
@ast
Pharmacodynamic modeling of time-dependent transduction systems.
@en
Pharmacodynamic modeling of time-dependent transduction systems.
@nl
type
label
Pharmacodynamic modeling of time-dependent transduction systems.
@ast
Pharmacodynamic modeling of time-dependent transduction systems.
@en
Pharmacodynamic modeling of time-dependent transduction systems.
@nl
prefLabel
Pharmacodynamic modeling of time-dependent transduction systems.
@ast
Pharmacodynamic modeling of time-dependent transduction systems.
@en
Pharmacodynamic modeling of time-dependent transduction systems.
@nl
P356
P1476
Pharmacodynamic modeling of time-dependent transduction systems.
@en
P2093
P304
P356
10.1067/MCP.2001.118244
P407
P577
2001-09-01T00:00:00Z